Purespring Therapeutics is a gene therapy company that provides treatments for different kidney diseases.
Purespring Therapeutics has raised $104.5M in total funding. The most recent round was Series B. The last funding was announced in October 2024.
Purespring Therapeutics's investors include Sofinnova Partners, Forbion Capital Partners, Gilde Healthcare, British Patient Capital, Syncona Partners LLP.
Purespring Therapeutics is headquartered in London, United Kingdom.
Purespring Therapeutics is a gene therapy company that provides treatments for different kidney diseases.
Purespring Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Purespring Therapeutics — Funding & Investors." VCBacked, October 9, 2024, https://www.vcbacked.co/company/purespring-therapeutics. Accessed August 1, 2026.
VCBacked. (2024). Purespring Therapeutics — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/purespring-therapeutics
{{cite web |title=Purespring Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/purespring-therapeutics |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated